This distinguishes SLAMF6 from many existing AML targets such as CD33, CD47, CD96, CD123, C-type lectin-like molecule 1 and TIM3, which are all expressed to various degrees on HSPCs2. Here, CD33 is linked to acute myeloid leukemia.